Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions?

Arch Dermatol Res. 2021 Mar;313(2):127-128. doi: 10.1007/s00403-020-02103-z. Epub 2020 Jul 9.

Authors

M Talamonti^#^{1

2}, L Tofani^#^{3

4}, L Bianchi^#^{3

4}, M Galluzzo^#^{3

5}

Affiliations

¹ Dermatology Unit, Fondazione Policlinico Tor Vergata, Rome, Italy. talamonti.marina@gmail.com.
² Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy. talamonti.marina@gmail.com.
³ Dermatology Unit, Fondazione Policlinico Tor Vergata, Rome, Italy.
⁴ Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.
⁵ Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy.

^# Contributed equally.

No abstract available

Publication types

Letter

MeSH terms

Anti-Inflammatory Agents, Non-Steroidal / adverse effects
Biological Factors / administration & dosage
Biological Factors / adverse effects
COVID-19 / complications*
COVID-19 / epidemiology
COVID-19 / immunology
COVID-19 / virology
Clinical Decision-Making
Comorbidity
Cytokine Release Syndrome / immunology
Cytokine Release Syndrome / prevention & control*
Dermatology / standards
Dose-Response Relationship, Drug
Humans
Immunosuppressive Agents / administration & dosage
Immunosuppressive Agents / adverse effects
Patient Selection
Practice Guidelines as Topic*
Psoriasis / drug therapy*
Psoriasis / epidemiology
Psoriasis / immunology
Risk Assessment
Risk Factors
SARS-CoV-2 / immunology
Societies, Medical / standards
Thalidomide / administration & dosage
Thalidomide / adverse effects
Thalidomide / analogs & derivatives
Withholding Treatment / standards*

Substances

Anti-Inflammatory Agents, Non-Steroidal
Biological Factors
Immunosuppressive Agents
Thalidomide
apremilast